Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie ...
Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...
Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...
Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP-1 drugs while facing potential legal challenges.
Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...
German CDMO Rentschler Biopharma is closing down its cell and gene therapy operations and shutting a facility in the UK, which could affect up to 30 employees.
Several months into a multiyear quest to “rigorously prioritize” its pipeline, Takeda is cutting a handful of programs. The company revealed the changes on Thursday … ...
API maker Bright Green plans $3.5B US facilities; EU launches biotech hub; Q4 earnings from Thermo Fisher, Sartorius, Danaher; Piramal reports growth; Upperton completes UK site ...
Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.
Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.
Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart disease called pulmonary hypertension in heart failure with preserved ejection ...
VC, a venture capital firm that has spread its bets across multiple industries, including biotech and digital health, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback